FOOD AND DRUG ADMINISTRATION

News

  • FDA accuses Ranbaxy's Paonta Sahib Plant of falsifying data

    FDA accuses Ranbaxy's Paonta Sahib Plant of falsifying data

    THE US Food and Drug Administration (FDA) FDA charged Ranbaxy Laboratories’, Paonta Sahib facility, India has falsified data and test results in approved and pending drug applications.

    13/03/2009

  • FDA keeps tabs on fraudulent H1N1 Influenza products

    The Food and Drug Administration (FDA) publishes a listing of fraudulent 2009 H1N1 Influenza products that have not been approved for diagnosis, prevention or treatment.

    27/11/2009

  • FDA approves surgical adhesion barrier

    FDA approves surgical adhesion barrier

    SYNTHEMED has announced that the US Food and Drug Administration (FDA) has approved the Pre-market Approval (PMA) application for REPEL-CV Adhesion Barrier.

    13/03/2009

  • FDA warns of complications with Negative Pressure Wound Therapy systems

    The Food and Drug Administration (FDA) has issued safety information regarding Negative Pressure Wound Therapy (NPWT) systems. Healthcare professionals have been notified by the US authority regarding deaths and serious complications associated with the use of these systems.

    24/11/2009

  • FDA finalises guidance for medical device investigators

    The US Food and Drug Administration (FDA) A has finalised a paper titled 'Guidance for Industry Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects', which includes an attachment specifically for those involved in medical device trials and their management.

    05/11/2009

  • China’s rabies vaccines confiscated

    China’s rabies vaccines confiscated

    CHINA Bio-Immunity Corporation (CHHB) has announced an update regarding the nationwide recall of its rabies vaccines.

    13/03/2009

  • CSL Behring drug RiaSTAP gains seven years of exclusivity

    CSL Behring drug RiaSTAP gains seven years of exclusivity

    CSL Behring has been informed by the US Food and Drug Administration (FDA), that its RiaSTAP drug is entitled to seven years of ‘orphan-drug exclusivity.’

    16/03/2009

  • ChemImage aids drug developers achieve nasal spray bioequivalence

    ChemImage aids drug developers achieve nasal spray bioequivalence

    CHEMIMAGE has announced it will aid generic drug makers achieve bioequivalence for nasal spray suspensions and inhalation products by providing a faster and more accurate way to determine drug particle size distribution in a drug product.

    20/03/2009

  • Vanda releases antipsychotics effect on schizophrenia report

    Vanda releases antipsychotics effect on schizophrenia report

    VANDA Pharmaceuticals has compiled a report titled the “Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia" for Schizophrenia Research, the official journal of the Schizophrenia International Research Society.

    13/03/2009

  • Slowing down beta cell destruction in Type 1 diabetics

    US researchers have found that injections of the drug rituximab slows down beta cell destruction in the pancreas of patients newly diagnosed with type 1 diabetes for at least a year. The findings suggest a potential treatment option that might improve management and reduce long-term complications of the disease.

    10/12/2009

  • Prostate cancer device poised for US market

    University of Wollongong (UOW) researchers have developed a prostate cancer treatment device to enhance a US company’s Prostate Immobilizer Balloon System.

    09/11/2009

  • US blood test detects early-stage colon cancer

    A US biotech company, EDP Biotech (EDP), has developed a new technology for detecting early-stage colon cancer. EDP says the blood test is inexpensive and can detect colon cancer in its earliest, most curable stages.

    16/02/2010

  • FDA approves broader spectrum pneumococcal vaccine for infants

    The US Food and Drug Administration (FDA) has approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years. This new vaccine extends the protection to six more types of the disease-causing bacteria than its predecessor Prevnar.

    01/03/2010

  • Stanford researchers develop model for medical device development process

    RESEARCHERS at Stanford University have published a comprehensive model representing the medical device development process, in an effort to help companies execute the bench-to-bedside process of product development.

    02/07/2009

  • Shering-Plough hepatitis C therapy FDA approved

    Shering-Plough hepatitis C therapy FDA approved

    SCHERING-PLOUGH today announced that the US Food and Drug Administration (FDA) has approved new labelling for its PEGINTRON (peginterferon alfa-2b) and REBETOL (ribavirin, USP) combination therapy for treating chronic hepatitis C in patients three years of age and older with compensated liver disease.

    16/03/2009

  • Medtronic recognised for its deep brain stimulation device

    Medtronic has been selected as one of Massachusetts Institute of Technology (MIT) Technology Review's 50 most innovative companies. The company was recognised for its development and introduction of Deep Brain Stimulation (DBS) Therapy, which helps treat neurological conditions by delivering controlled electrical pulses to a specific part of the brain.

    05/03/2010

  • Device helps paralysed patients breathe easier

    US physicians will soon begin implanting a new medical device to improve breathing in patients with upper spinal-cord injuries or conditions that keep them from breathing independently.

    30/11/2009

  • Clinical trial begins for patient-specific vaccine to treat NHL

    Clinical trial begins for patient-specific vaccine to treat NHL

    Bayer has begun a clinical Phase I study to treat non-Hodgkins lymphoma (NHL) using a patient-specific vaccine derived from tobacco plants.

    12/02/2010

  • FDA approves vaccine for meningococcal disease

    Menveo, a quadrivalent meningococcal conjugate vaccine from Novartis, has been approved by the US Food and Drug Administration (FDA) for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people 11 to 55 years of age.

    01/03/2010

  • New stent helps keep vessels open for dialysis

    A new stent graft can open vessels that become blocked or narrowed at the point where dialysis machines connect to the body. The stent has received approval from the US Food and Drug Administration.

    16/02/2010

 

Products

 

Find more information about Food and Drug Administration on our other sites.

to get Medical Devices Equipment
delivered to your inbox

Latest from Twitter

    Getting your tweets...